Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Imamura

Showing results (381-390 of 395) with videos related to

Pageof 40
Sort By:
Medicine|June 11, 2021
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapyYuya Hirasawa, Kiyoshi Yoshimura, Hiroto Matsui, et al.
International Journal of Clinical Oncology|November 21, 2024
Clinical benefits of adding olanzapine to 5-HT<sub>3</sub> receptor antagonist, NK<sub>1</sub> receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical OncologyMichiyasu Murakami, Yoshiharu Miyata, Kazuhisa Nakashima, et al.
International Journal of Clinical Oncology|May 9, 2024
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023Masamitsu Kobayashi, Jun Kako, Arisa Iba, et al.
International Journal of Clinical Oncology|September 28, 2024
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical OncologyAyako Yokomizo, Kazuhisa Nakashima, Arisa Iba, et al.
International Journal of Clinical Oncology|September 11, 2024
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncologyToshinobu Hayashi, Shun Yamamoto, Yoshiharu Miyata, et al.
Pediatric Blood & Cancer|February 25, 2026
Combined Tyrosine Kinase Inhibitors and Chemotherapy Based on Minimal Residual Disease in Children With Ph<sup>+</sup> Acute Lymphoblastic Leukemia: A Phase 2 Single-Arm Trial, JCCG ALL-Ph13Atsushi Sato, Yuichi Kodama, Hirohide Kawasaki, et al.
International Journal of Clinical Oncology|November 12, 2024
Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologyKazuhisa Nakashima, Saki Harashima, Rena Kaneko, et al.
Clinical Chemistry and Laboratory Medicine|May 15, 2001
Standardization of laboratory data and establishment of reference intervals in the Fukuoka Prefecture: a Japanese perspectiveS Kinoshita, M Toyofuku, H Iida, et al.
International Journal of Clinical Oncology|November 8, 2020
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015  Japan Society of Clinical Oncology Clinical Practice Guidelines for AntiemesisKenjiro Aogi, Hideki Takeuchi, Toshiaki Saeki, et al.
International Journal of Clinical Oncology|October 17, 2024
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologyKazuhisa Nakashima, Ayako Yokomizo, Michiyasu Murakami, et al.
Pageof 40

Showing results (381-390 of 395) with videos related to

Sort By:
Pageof 40
Medicine|June 11, 2021
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapyYuya Hirasawa, Kiyoshi Yoshimura, Hiroto Matsui, et al.
International Journal of Clinical Oncology|November 21, 2024
Clinical benefits of adding olanzapine to 5-HT<sub>3</sub> receptor antagonist, NK<sub>1</sub> receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical OncologyMichiyasu Murakami, Yoshiharu Miyata, Kazuhisa Nakashima, et al.
International Journal of Clinical Oncology|May 9, 2024
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023Masamitsu Kobayashi, Jun Kako, Arisa Iba, et al.
International Journal of Clinical Oncology|September 28, 2024
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical OncologyAyako Yokomizo, Kazuhisa Nakashima, Arisa Iba, et al.
International Journal of Clinical Oncology|September 11, 2024
Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncologyToshinobu Hayashi, Shun Yamamoto, Yoshiharu Miyata, et al.
Pediatric Blood & Cancer|February 25, 2026
Combined Tyrosine Kinase Inhibitors and Chemotherapy Based on Minimal Residual Disease in Children With Ph<sup>+</sup> Acute Lymphoblastic Leukemia: A Phase 2 Single-Arm Trial, JCCG ALL-Ph13Atsushi Sato, Yuichi Kodama, Hirohide Kawasaki, et al.
International Journal of Clinical Oncology|November 12, 2024
Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologyKazuhisa Nakashima, Saki Harashima, Rena Kaneko, et al.
Clinical Chemistry and Laboratory Medicine|May 15, 2001
Standardization of laboratory data and establishment of reference intervals in the Fukuoka Prefecture: a Japanese perspectiveS Kinoshita, M Toyofuku, H Iida, et al.
International Journal of Clinical Oncology|November 8, 2020
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015  Japan Society of Clinical Oncology Clinical Practice Guidelines for AntiemesisKenjiro Aogi, Hideki Takeuchi, Toshiaki Saeki, et al.
International Journal of Clinical Oncology|October 17, 2024
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologyKazuhisa Nakashima, Ayako Yokomizo, Michiyasu Murakami, et al.
Pageof 40